Please ensure Javascript is enabled for purposes of website accessibility

Why Denali Therapeutics Stock Popped Today

By Keith Speights - Mar 11, 2021 at 3:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech received good news from the FDA concerning one of its pipeline candidates.

What happened

Shares of Denali Therapeutics (DNLI -7.68%) popped on Thursday, with the stock rising 12.3% as of 3:28 p.m. EST. The nice gain came after the biotech announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to DNL310 in treating Hunter syndrome, which is also known as mucopolysaccharidosis type II (MPS II).

So what

The old adage that time is money applies to biotech stocks. Fast Track designation for DNL310 should speed up the process for DNL310 to potentially ultimately win regulatory approval.

Man wearing a coat and tie holding blocks spelling FDA

Image source: Getty Images.

The FDA established the Fast Track program to expedite the review of drugs that target serious conditions and that fill an unmet medical need. DNL310 certainly meets those criteria. Hunter syndrome is a rare genetic disease that can lead to neurodegeneration and damage to organs including the heart and lungs. Although enzyme replacement is currently used to treat the disease, the therapies don't cross the blood-brain barrier. As a result, they don't address the central nervous system symptoms of Hunter syndrome.  

Denali is currently evaluating DNL310 in a phase 1/2 clinical study. The company also has another early-stage clinical program for DNL151, which targets the treatment of Parkinson's disease.

Now what

Several major pipeline milestones should be on the way for Denali. The company plans to add a third cohort to its phase 1/2 study of DNL310. Denali and Biogen should advance DNL151 into late-stage testing by the end of this year. In addition, the company anticipates kicking off a phase 1b study of DNL343 in treating neurodegenerative disease amyotrophic lateral sclerosis (ALS) in the second half of 2021. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Denali Therapeutics Inc. Stock Quote
Denali Therapeutics Inc.
DNLI
$23.19 (-7.68%) $-1.93
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$195.71 (-3.54%) $-7.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.